Guggenheim Initiates Coverage On UroGen Pharma with Buy Rating, Announces Price Target of $40

-3.93%

UroGen Pharma Ltd.

URGN

0.00

Guggenheim analyst Kelsey Goodwin initiates coverage on UroGen Pharma (NASDAQ: URGN) with a Buy rating and announces Price Target of $40.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Berkshire Earnings Released! Cash Reserves Exceed $380 Billion, New Record High—Top 5 Holdings Revealed

Post Holdings (POST): Assessing Valuation After Shareholder Rights Update

Charles River Laboratories (CRL): Exploring Valuation After New Drug Discovery Collaborations Boost Innovation Prospects

Does the Recent 9.3% Drop Create Opportunity in Liberty Latin America Stock?

Is Tesla's Valuation Justified After Its 83% Surge and Self-Driving Advances?

Tradeweb (TW) Hits Revenue Record and Expands Globally Is Its Innovation Edge Sustainable?

Will RBC Bearings' (RBC) Third-Quarter Growth Guidance Reshape Analyst Expectations for Long-Term Earnings?

PJT Partners (PJT): Examining Valuation Following Recent Share Price Decline